Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3247-3255

  Peklak Scott, Christina ^a   Smitherman, Pamela K ^a   Townsend, Alan J ^a   Morrow, Charles S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE;

ALLELE; ARTICLE; CANCER RESISTANCE; CATALYSIS; CELL STRAIN MCF 7; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CELL DEATH; CHEMISTRY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG RESISTANCE; GENETIC TRANSDUCTION; MASS SPECTROMETRY; METABOLISM; TUMOR CELL LINE;

ALLELES; CATALYSIS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MASS SPECTROMETRY; METABOLIC DETOXICATION, DRUG; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TRANSDUCTION, GENETIC;

EID: 55749097955     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0250     Document Type: Article

References (51)

1. Kufe DW, Bast RC, Hait WN, et al. Cancer medicine. 7th ed. Hamilton (Ontario, Canada): BC Decker; 2006.
2. Zlatanova J, Yaneva J, Leuba SH. Proteins that specifically recognize cisplatin-damaged DNA: a clue toantica ncer activity of cisplatin. FASEB J 1998;12:791-9.
3. Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 1985;24:7533-40.
4. Demarcq C, Bunch RT, Creswell D, Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 1994;5:983-93.
5. Mello JA, Lippard SJ, Essigmann JM. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 1995;34:14783-91.
6. Kartalou M, Essigmann J. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
7. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
8. Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 2001;59:837-43.
9. Bernareggi A, Torti L, Facino R, et al. Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats and cancer patients. J Chromatogr B Biomed Appl 1995;669:247-63.
10. Hagrman D, Goodisman J, Souid A-K. Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 2004;308:658-66.
11. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993;268:20116-25.
12. Townsend DM, Marto JA, Deng M, Macdonald TJ, Hanigan MH. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of cisplatin. Drug Metab Dispos 2003;31:705-13.
13. Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996;56:3577-82.
14. Ishimoto T, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli . Pharmacogenetics 2002;12:543-53.
15. Miyazaki M, Kohno K, Saburi Y, et al. Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase π gene. Biochem Biophys Res Commun 1990;166:1358-64.
16. Nishimura T, Newkirk K, Sessions RB, et al. Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact 1998;111-112:187-98.
17. Saburi Y, Nakagawa M, Ono M, et al. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res 1989;49:7020-5.
18. Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T. Overexpression of glutathione S-transferase π enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999;31:549-58.
19. Ahmad H, Wilson DE, Fritz RR, et al. Primary and secondary structural analyses of glutathione S-transferase π from human placenta. Arch Biochem Biophys 1990;278:398-408.
20. Ali-Osman F, Akande O, Antoun G, Mao J-X, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π gene variants. J Biol Chem 1997;272:10004-12.
21. Hu X, Herzog C, Zimniak P, Singh SV. Differential protection against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage in HepG2 cells stably transfected with allelic variants of π class human glutathione S-transferase. Cancer Res 1999;59:2358-62.
22. Hu X, Ji XH, Srivastava SK, et al. Mechanism of differential catalytic efficiency of two polymorphic forms of human glutathione S-transferase P1 in glutathione conjugation of carcinogenic diol epoxide of chrysene. Arch Biochem Biophys 1997;345:32-8.
23. Hu X, Xia H, Srivastava SK, et al. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997;238:397-402.
24. Maugard CM, Charrier J, Pitard A, et al. Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer 2001;91:334-9.
25. Park JY, Schantz SP, Stern JC, Kaur T, Lazarus P. Association between glutathione S-transferase π genetic polymorphisms and oral cancer risk. Pharmacogenetics 1999;9:497-504.
26. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 1992;17:463-8.
27. Morrow CS, Diah S, Smitherman PK, Schneider E, Townsend AJ. Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 1998;19:109-15.
28. Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem 1998;273:20114-20.
29. Morrow CS, Smitherman PK, Townsend AJ. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog 2000;29:170-8.
30. Paumi C, Smitherman P, Townsend A, Morrow C. glutathione S-transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferator-activated receptor γ (PPARγ) ligand, 15-deoxy-Δ(12,14)prosta-(12,14)prostaglandin J(2) (15-d-PGJ(2)). Biochemistry 2004;43:2345-52.
31. Paumi CM, Wright M, Townsend AJ, Morrow CS. Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Δ(12,14)prostaglandin J(2) in MCF7 breast cancer cells. Biochemistry 2003;42:5429-37.
32. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
34. Habig W, Pabst M, Jakoby W. Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130-9.
35. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increased resistance tonatural product drugs. Cancer Res 1994;54:357-61.
36. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
37. Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57:5475-9.
38. Minamino T, Tamai M, Itoh Y, et al. In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT). Jpn J Cancer Res 1999;90:1171-8.
39. Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer res 1996;56:4124-9.
40. Odenheimer B, Wolf W. Reactions of cisplatin with sulfur-containing amino acids and peptides. I. Cysteine and glutathione. Inorganica Chim Acta 1982;66:L41-3.
41. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18:1321-34.
42. Wu Y, Fan Y, Xue B, et al. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-1 signals. Oncogene 2006;25:5787-800.
43. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000;60:4053-7.
44. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC, Perona R. Cell stress and MEKK1-mediated c-Jun activation modulate NFκB activity and cell viability. Mol Biol Cell 2002;13:2933-45.
45. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998;16:533-40.
46. Wang Z, Xu J, Zhou J-Y, Liu Y, Wu GS. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006;66:8870-7.
47. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 2004;65:235-43.
48. 2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003;278:20582-92.
49. Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997;272:14041-4.
50. Levresse V, Marek L, Blumberg D, Heasley LE. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol Pharmacol 2002;62:689-97.
51. Elsby R, Kitteringham NR, Goldring CE, et al. Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase π. J Biol Chem 2003;278:22243-9.